---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-020405"
form_type: "8-K/A"
ticker: "MRKR"
cik: "0001094038"
company_name: "Marker Therapeutics, Inc."
filed_at: "2025-03-04T23:59:59+00:00"
generated_at: "2026-05-25T12:40:16.896168+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Marker Therapeutics corrects option grant date to Feb 12, 2025; awards options to CEO and directors

## Summary
- CEO Dr. Juan Vera receives 50,000 stock options vesting annually over three years.
- Non-employee directors David Eansor, Katherine Knobil, Steven Elms each receive 30,000 options.
- Amendment corrects prior filing: grant date changed from Feb 12, 2024 to Feb 12, 2025.
- All options are under the 2020 Omnibus Stock Ownership Plan and standard award agreement.

## SEC filing metadata
- accession: 0001104659-25-020405
- form_type: 8-K/A
- ticker: MRKR
- cik: 0001094038
- company_name: Marker Therapeutics, Inc.
- filed_at: 2025-03-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.25
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1094038/000110465925020405/0001104659-25-020405-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1094038/000110465925020405/tm258250d1_8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-020405
- JSON: https://secwatch.observer/filing/0001104659-25-020405.json
- Plain text: https://secwatch.observer/filing/0001104659-25-020405.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.